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Background: P19 H-Ras, a second product derived from the H-Ras gene by alternative splicing, induces a G1/S
phase delay, thereby maintaining cells in a reversible quiescence state. When P21 H-Ras is mutated in tumour cells,
the alternative protein P19 H-Ras is also mutated. The H-Ras mutation Q61L is frequently detected in different
tumours, which acts as constitutive activator of Ras functions and is considered to be a strong activating mutant.
Additionally, a rare congenital disorder named Costello Syndrome, is described as a H-Ras disorder in children,
mainly due to mutation G12S in p19 and p21 H-Ras proteins, which is present in 90 % of the Costello Syndrome
patients. Our aim is to better understand the role of p19 and p21 H-Ras proteins in the cancer and Costello
Syndrome development, concerning the miRNAs expression.
Methods: Total miRNAs expression regulated by H-Ras proteins were first analyzed in human miRNA microarrays
assays. Previously selected miRNAs, were further analyzed in developed cell lines containing H-Ras protein mutants,
that included the G12S Costello Syndrome mutant, with PCR Real-Time Taq Man miRNA Assays primers.
Results: This study describes how p19 affects the RNA world and shows that: i) miR-342, miR-206, miR-330, miR-138
and miR-99b are upregulated by p19 but not by p19W164A mutant; ii) anti-miR-206 can restore the G2 phase in
the presence of p19; iii) p19 and p21Q61L regulate their own alternative splicing; iv) miR-206 and miR-138 are
differentially regulated by p19 and p21 H-Ras and v) P19G12S Costello mutants show a clear upregulation of
miR-374, miR-126, miR-342, miR-330, miR-335 and let-7.
Conclusions: These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA
expression and open up a new line of study to understand the consequences of this mutation on Costello
syndrome. Furthermore, they suggest that oncogenes may have a sufficiently important impact on miRNA
expression to promote the development of numerous cancers.
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Ras, an important family of proto-oncogenes in humans,
consists of three members (H-Ras, N-Ras and K-Ras) lo-
cated on human chromosomes 1, 11 and 12 respectively
[1–3]. Indeed, Ras gene mutations have been implicated
in up to 30 % of all tumours tested. These mutations are
different and depend on the tissues involved but most* Correspondence: montse.bach@iibb.csic.es
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(30 %). A point mutation in Ras codons converts these
genes into active oncogenes as a result of decreased
GTPase activity, thereby restricting the easy interchange
of GDP to GTP and resulting in a constitutive activation
of the downstream pathways, or loss of GAP function.
Ras mutated proteins are indirectly involved in metasta-
sic phenotype development as they promote the acquisi-
tion of cumulative alterations in cellular pathways which
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sation into lymphatic and blood vessels, and finally apop-
tosis evasion [4].
The H-Ras gene codifies for two different proteins,
namely p19 H-Ras and p21 H-Ras, by alternative spli-
cing [5–7]. The mRNA structures of these alternative se-
quences are identical in their first coding exons (called
1, 2, 3 and 4A) and have two non-codifying exons (0 and
4B located at the 5′-UTR and 3′-UTR regions, respect-
ively) separated by intronic regions designated as A-E.
The alternative exon, known as IDX (intron-D-exon, 82
nucleotides), is located between exons 3 and 4A. The
pre-mRNA H-Ras is processed into two mRNAs, namely
p21 mRNA, which excludes the IDX exon, and p19
mRNA, which includes it [5–7]. p19 mRNA therefore
codes for a shorter protein than p21 mRNA. Further-
more, since IDX exon contains a premature stop codon,
p19 does not contain the CAAX motif [6]. p19 H-Ras
induces a G1/S phase delay, thereby maintaining cells in
a reversible quiescence state [7]. p19 Binds to RACK1
and regulates telomerase activity upon interaction with
p73α/β proteins as well as inducing hypophosphoryla-
tion of Akt and p70S6K and upregulating FOX1 [6, 7].
Although p19 overexpression does not induce apoptosis
[7], Kim et al. have shown that it stimulates p73β-induced
apoptosis when both proteins are simultaneously overex-
pressed [8]. RNAi of p19 increases cell growth, thereby
having an opposite effect to the delay in the G1/S phase
described above [7]. Other authors showed that p19 re-
presses proliferation on non-small cell lung cancer through
interaction with neuron-specific enolase (NSE) [9].
P19 was first described from in T24/EJ bladder carcin-
oma cell line that contains, in addition to G12V mutation,
a small number of other nucleotide changes including an
adenine (A) to guanine (G) mutation at position 2714.
This latter region was showed to regulate the alternative
splicing of H-Ras into two proteins, p21 and p19. The
2719 mutation decresed the p19 expression, and this mu-
tation promotes 10-fold increase of p21 H-Ras levels and
a corresponding increase of the transforming efficiency of
structurally activated alleles [5, 10].
The H-Ras mutation Q61L is frequently detected in
different tumour cell lines, where it acts as a constitutive
activator of the Ras-signalling pathway and is considered
to be a strong activating mutant by decreasing GTPAse
activity and increasing GDP/GTP exchange [1, 11, 12].
G12S, another important H-Ras mutation is, present in
more than 90 % of patients with Costello Syndrome (CS),
a rare congenital disorder caused by germ-line activation
of H-Ras oncogenes that affects both p19 and p21 H-Ras
[13]. CS is characterized by severe failure-to-thrive, car-
diac abnormalities, including tachyarrhythmia and hyper-
trophic cardiomyopathy, a predisposition to papillomata
and malignant tumours, and neurologic abnormalities,including nystagmus, hypotonia developmental delay, and
mental retardation [14–18].
To better understand the role of p19 and p21 H-Ras
proteins in the development of cancer, we transfected
HeLa cells with p19 and p21 mutant sequences, which
were reported in the literature to be commonly detected
in tumour cell lines and in CS (G12S). We also evaluated
the expression of selected miRNAs [19] involved in some
aspects of metastasis and others related with aggressive
small cell lung cancer.
Methods
Cell lines, cell transfection and antibodies
HeLa cells were cultured and transiently transfected as
described elsewhere [6, 7]. Knock-out murine embryonic
fibroblasts (MEFs) H-Ras−/− (KO) and double knock-out
MEFs H-Ras−/− plus N-Ras−/− (DKO) were obtained from
Dr. E. Santos’s laboratory [20]. KO and DKO cell lines,
stably expressing pEGFP (negative control), pEGFP-p19
and pEGFP-21, were obtained by transfecting the fibro-
blasts with the specific vector and selecting with geneticin.
Plasmids
pEGFP-p19 and -p21, pRK5-p19 and pRK5-p19W164A
have been described previously [6, 7], therefore the other
pRK5 plasmids were obtained in a similar manner [6, 7].
Other point mutations of p19 H-Ras and p21 H-Ras were
performed by polymerase chain reaction site-directed mu-
tagenesis using the QuickChange® Site-Directed mutagen-
esis kit from Stratagene.
Isolation of small RNAs
miRNAs were extracted using the miRVANA™ miRNA
isolation kit from Ambion Inc. (Austin, Tx). Isolation was
performed as described by the manufacturer’s protocol.
miRNA microarrays
miRNA microarrays were performed as described previ-
ously [21].
miRNA Reverse Transcriptase (RT) reaction
cDNA was reverse-transcribed from enriched miRNA sam-
ples (miRVANA kit) using specific miRNA primers from
the Taq Man MicroRNA Assay and reagents from the Taq
Man MicroRNA RT kit (AB Applied Bio systems) accord-
ing to the manufacturer’s instructions. Briefly, 1.33 μL of
each resulting cDNA was amplified by PCR using Taq Man
MicroRNA Assay primers with the Taq Man Universal
Non amperase PCR Master Mix (in a total volume of
20 μL) and analyzed with a 7500 ABI PRISM Sequence
Detector System according to the manufacturer’s instruc-
tions. miRNA expression was calculated from the relevant
signals by normalization with respect to the signal for U18
(for HeLa cells) and U6 for MEFs. Stem-loop quantitative
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previously using an Applied Biosystems ABI 7500 Real
Time PCR system. All RT-PCR reactions were run in trip-
licate and gene expression, relative to U18, calculated
using the 2-ΔΔCt method [22].
Real time TAQMAN RT-PCR assays of mRNAs
Total RNA was extracted from 10 × 105 HeLa cells using
TRIZOL reagent (Life Technologies, Inc.), as described
previously. cDNA was reverse-transcribed from total RNA
samples using SuperScriptIII® from Invitrogen. The result-
ing cDNA was amplified by PCR using Taq Man Assay
primers with the Taq Man Universal Non-amperase PCR
Master Mix and analyzed with a 7500 ABI PRISM Se-
quence Detector System according to the manufacturer’s
instructions. mRNA expression was calculated from the
relevant signals by normalization with respect to the signal
for glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA expression. The assay numbers for exons E3-IDX
p19 H-Ras (Hs00978053_g1), E4A-E4B H-Ras total
(Hs00978051_g1) and E3-E4A p21 H-Ras (Hs00610483_m1)
and for GAPDH (HS99999905_m1 housekeeping) were
supplied by Applied Biosystems Gene Expression Assays
(Applied Biosystems). Assays were run withTaqman Universal.
Western blot analysis, cell-proliferation assay and
determination of cell-cycle phase percentages
These assays were performed as described previously [6, 7].
Ethics approval
No ethics approval was required for aspects of this study.
Results
P19 overexpression regulates specific miRNA expression
We have shown previously that cell growth and meta-
static genes are regulated by p19 [7]. In this latter work
we compared p19 expression with the specific p19mut
expression (mutation not seen in p21), where p19mut
was a p19 mutant (W164A) that prevented p19-RACK1
and p19-p73α binding [7]. These previous analysis are
further complemented here by checking whether p19
can regulate other RNA genes by studying miRNA ex-
pression in cells overexpressing p19 or p19mut. First, we
incubated miRNA micro-arrays with RNAs from cells
overexpressing p19 wild-type protein versus RNAs from
cells overexpressing empty vector. A second incubation
was performed with RNAs from cells overexpressing
p19mut in a similar way. Afterwards, both results were
mathematically compared, and miRNAs that are upregu-
lated by p19 overexpression but not by 19mut overex-
pression were selected (see Fig. 1a). Candidate miRNAs
were found to be miR-342, miR-206, miR-330, miR-138,
and mirR-99b (Fig. 1a and Additional file 1), which vary
with p19 but not with the specific p19mut overexpression.We consider that the values obtained with p19mut over-
expression could be considered the miRNAs basal levels
respect p19 wild-type protein (see asterisks values in
Fig. 1a and Additional file 1). The most relevant observa-
tion of this assay is that the expression of very few miRNAs
varies upon overexpression of p19 and not by p19mut over-
expression and so, these miRNAs might be also related to
the pathway process activated by RACK-p19 and p73α-p19
interactions. miRNA upregulation by p19 H-Ras was re-
validated by RT-PCR with a specific Taqman assay for ma-
ture miR-206, miR-342, miR-138 and miR-330 and was
found to increase 2-, 1.6-, 16- and 2.5-fold, respectively,
upon overexpression of p19 in three independent experi-
ments and quadruplicate analysis. miR-206 has been reported
to be the miRNA whose expression is most downregulated
in metastatic cells and has also been shown to regulate
cell migration and morphology [23]. Our previous work
showed that p19 H-Ras induces a G1/S phase delay, thereby
maintaining cells in a reversible quiescence state [7]. Taken
together, these findings prompted us to study the contri-
bution of miR-206 upregulation to the G1/S delay, both of
which are induced by p19. Figure 1b shows that anti-miR-
206 partially antagonizes the effect of p19 on G1/S phases
and restores the G2 phase, thus indicating that miR-206
upregulation partially contributes to the G1/S delay ob-
served upon p19 overexpression.
H-Ras mutants alter the H-Ras splicing rate
We have previously demonstrated that SR proteins
(SFRs) activate inclusion of the alternative exon IDX and
subsequently p19 expression [6, 24]. p68 RNA helicase
(DDX5) was also shown to inhibit p19 expression and re-
duce IDX inclusion, whereas SC-35 (SFRS2) and SRp40
(SFRS5) strongly increase IDX inclusion in vivo [6, 24].
We analyzed the obtained miRNAs by the TARGETSCAN
tool and observed that miR-330 may target SC-35 and
many other SR proteins as well as an UsnRNP core pro-
tein, mir-342 may target SF4, and miR-206 may target p68
RNA helicase and many other SR proteins. As splicing
factors are also targets of the miRNAs upregulated by p19,
therefore we decided to study whether the overexpression
of p19 can also affect its own alternative splicing. Thus,
two Taqman RT-PCR assays were designed to map total/
endogenous H-Ras mRNA (directed to E3-E4A exons)
and the endogenous p19 level and the endogenous/total
p21 H-Ras ratio determined in HeLa cells transiently over-
expressing p19 (see Fig. 2a). Figure 2b shows that overex-
pression of p19 increases total endogenous H-Ras and
endogenous p21 expression by 5.3- and 3.9-fold, respect-
ively, and that this activation is reverted to endogenous
basal levels by p19mut. The splicing rate for endogenous
p21 formation was slightly reduced in cells overexpressing
p19 (Fig. 2b) but increased in the presence of p19mut
(10 % higher than the negative control), thus indicating
Fig. 1 Anti-miR-206 partially antagonizes the effect of p19 on G1/S
and G2 phases. a Fold change is the value used to measure
overexpression of pRK5-p19 as compared first to pRK5 empty vector
and then to overexpression of pRK5-p19mut for miRNA microarrays.
(*) indicates the value obtained with pRK5-p19mut. These miRNAs
varies upon overexpression of 19 and not by p19mut overexpression.
Additional gene information is available in Additional file 1 (P < 0.01).
RT: miR-206 activation was confirmed by Taqman RT-PCR with a
specific Taqman assay for mature miR-206 (Applied Biosystems).
b HeLa cells were first transfected with the pSuper-GFP vector
containing the sequence of anti-miR-206 and incubated for 2 days
under cell-culture conditions. Cells were then re-transfected with
GFP-p19 vector and analyzed by FACS (fluorescent-activated cell
sorting) the following day. A representative flow cytometry histogram
with GFP-p19, pSuper-GFP anti-miR-206, GFP-p19 + pSuper-GFP
anti-miR-206 or GFP only (negative control) is shown in the upper
portion, whereas G1, S, and G2 percentages are given below
(*P < 0.001 as compared G1 and G2 to GFP-19 versus GFP-p19 +
anti-miR-206). HeLa cells line were used in all the experiments
stated above
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H-Ras alternative splicing processes. In contrast, p19 was
observed to directly regulate total mRNA H-Ras expres-
sion but not to significantly alter the splicing rate of H-
Ras pre-mRNA, thus indicating that the p19:p21 ratio is
maintained. Furthermore, we showed that the overexpres-
sion of the strong p21 mutant (p21Q61L) also regulated
this alternative splicing, increasing the amount of p19
mRNA (Fig. 2c).
P19 alters miRNAs expression but not the cell growth in
H-Ras(−/−) KO cell lines
In order to further understand how the alternative spli-
cing of H-Ras alters miRNAs, we differentially expressed
pEGFP-p19 or pEGFP-p21 in H-Ras(−/−) KO MEFs and
analyzed their effect on miR-206 and miR-138. Figure 3a
shows that p19 has a large effect on miR-206 expression
whereas pGFP-p21 increases it only slightly. pEGFP-p19
also has a large effect on miR-138 in both KO MEFs and
HeLa cells (Fig. 3b, c, respectively), thus indicating that the
alternative splicing of H-Ras towards p19 or p21 affects
the expression of several miRNAs. Figure 4 shows that
pEGFP-p21 increases cell growth in H-Ras(−/−)/N-Ras(−/−)
DKO MEFs whereas pEGFP-p19 does not. This finding is
in accordance with our previous results, where we showed
that p19 causes a G1/S delay in HeLa cells.
The p19 CS mutant G12S alters miRNA expression
Aoki et al. [25] reported that CS is a result of mutations
in the H-Ras gene. The most common mutation is found
on codon 12 with the amino acid change G12S [13]. All
human cells contain both p19 and p21 H-Ras proteins at
different levels as a consequence of the alternative splicing,
therefore when H-Ras gene is mutated in CS patients, both
ab
c
*
*
*
*
Fig. 2 Gene expression and alternative splicing regulation by H-Ras proteins. a Scheme of the Taqman assays used to determine endogenous
p19, p21, and endogenous total H-Ras mRNA expression. E3-IDX, E3-E4A, and E4A-E4B recognize endogenous p19 H-Ras, p21 H-Ras, and both
p19 and p21 H-Ras, respectively. Taqman assays were performed with E3-E4A and E4A-E4B for overexpressed p19 and with E3-IDX and E4A-E4B
for overexpressed p21mut. b Endogenous total H-Ras (Taqman E4A-E4B) and p21 (Taqman E3-E4A) mRNA levels change upon overexpression of
p19 and p19mut. The results are presented as fold changes with respect to basal levels obtained for empty vector transfections, which were set
to 1 (no change). Graphic: the percentage of alternative splicing p21/endogenous total H-Ras (Taqman E3-E4A/Taqman E4A-E4B) was obtained
for each individual experiment and standard deviations of three separate experiments calculated. (−) is the % p21 in transfections with empty
vector set to 33 %; (⇧) p19 and (⇧) p19mut, % is the p21 in HeLa cells overexpressing p19 and p19mut, respectively. (⇧) p19, P = 0.07; (⇧) p19mut,
P = 0.08. c Endogenous total H-Ras (Taqman E4A-E4B) and p19 (Taqman E3-IDX) mRNA level changes upon overexpression of p21Q61L. The
results are presented as fold changes with respect to the basal levels obtained for empty vector transfections, which were set to 1 (no change).
Graphic: the percentage of alternative splicing p19/total H-Ras (Taqman E3-IDX/Taqman E4A-E4B) was obtained for each individual experiment
and standard deviations of three separate experiments calculated. (−) is the % of p19 in transfections with empty vector was set to 15 %;
(⇧)p21mut is the % of p19 after expression of the p21mut (p21Q61L). P = 0.09. Hela cells line were used in all the experiments stated above
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forms. We obtained pRK5 plasmids containing p19(G12S)
and determined how this mutant alters a selected group of
miRNAs in HeLa cells. These miRNAs included miR-342
and miR-330, which are already known to be upregulated
by p19 overexpression (Fig. 1), miR-126 and miR-335, whichsignificantly reduce the ability of CN34-LM1 and CN34-
BoM1 cells to metastasize to the lung [23], miR-374,
which is known to be associated with aggressive small cell
lung cancer [26], and let-7, which targets Ras genes [27].
Figure 5 shows that p19(G12S) clearly upregulates all
these miRNAs (column 3), thus indicating that the p19 CS
Fig. 3 P19 and p21 H-Ras differentially regulate miR-206 and miR-138. a and b show KO H-Ras(−/−) fibroblasts stably expressing pEGFP (negative
control), pEGFP-p19 or pEGFP-p21. The regulation of miR-206 (a) and miR-138 (b) was analyzed in these cells with specific miRNA Taqman assays.
c Regulation of miR-138 in transient transfections in HeLa cells
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ing specific miRNA levels. We also analyzed how p21 mu-
tants affect the same set of miRNAs by overexpressing
PRK5-p21, pRK5-p21Q61L and pRK5-p21G12S in HeLa
cells. Figure 5 shows that p21 and p21 mutants also alter
expression of these miRNAs, although to a lesser extent
than p19G12S. Thus, p21 was found to upregulate miR-374,
miR-126, miR-342, miR-335 and let-7 but not miR-330,Fig. 4 P19 H-Ras does not activate cell growth. DKO H-Ras(−/−)/N-Ras(−/−)
fibroblasts that stably express pEGFP (negative control), pEGFP-p19 and
pEGFP-p21 were studied by direct cell-proliferation assay. Cells were
harvested and plated in 96 wells (10,000 cells/well) on six microplates
in sextuplicate and incubated at 37 °C, 5 % CO2 with DMEM/10 % FCS.
After the desired time, the microplates were washed and frozen.
Cells were quantified with the green fluorescent dye CyQuant
(Invitrogen) according to the manufacturer’s instructions. Fluorescence
measurements were performed using a microplate reader with
excitation at 485 nm and detection at 530 nnmand p21G12S was found to have the same effect as p21 on
miR-374, miR-342 and miR-126. In contrast, p21G12S
(column 5) was found to have no effect on miR-335 and
let-7 but upregulates miR-330, whereas p21 does not. This
indicates that p21 and p21 mutants do not have such a
linear effect as p19 and p19G12S but that both p19 and
p21 CS mutants alter the expression of several miRNAs,
which may contribute to the development of CS.
Discussion
Homeostatic regulation of H-Ras
Although p21 H-Ras mutants have been extensively
studied, this is not the case for specific p19 H-Ras mu-
tants. However, it is known that a mutation in the 5′
splice-site of the IDX exon of H-Ras (position 2719, A to
G change) induces a 10-fold increase in p21 H-Ras level
and a corresponding increase in the transforming activ-
ity in a bladder carcinoma cell line [10]. In addition, we
have previously reported that the mouse NIH 3 T3 cell
contains a mutation at position 165 which causes a D to
G change [6]. p19 overexpression activates full-length total
H-Ras and p21, although the endogenous p19:p21 ratio
due to alternative splicing remains relatively unchanged
(Fig. 2). This H-Ras and p21 activation is dependent on the
W164A amino acid (Fig. 2). Thus, whereas the specific
p19mut expression reverts endogenous total H-Ras to
basal levels, p19mut alters alternative splicing in favor of
p21. In this study, we also found that although the Q61L
mutation in p21 does not affect endogenous total H-Ras
expression, the Q61L mutation on p21 produces a clear
Fig. 5 P19 H-RasG12S CS mutant clearly upregulates several miRNAs. HeLa cells transiently expressing: 1) pRK5 (negative control); 2) pRK5-p19;
3) pRK5-p19G12S; 4) pRK5-p21; 5) pRK5-p21Q61L; and 6) pRK5-p21G12S. MiRNAs levels were analyzed with specific miRNAs Taqman assays. Three
independent experiments were done, each of them per quadruplicate (n = 12, and statistic significative difference calculated by Anova, one way
analysis of variance, p <0.05, p value = 0.036), GraphPad Prism version 4.0
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mRNA compared to wild-type. We can therefore conclude
that the observed altered alternative splicing may act as a
homeostatic response mechanism. We have also found
that few proteins or miRNA genes are up- or downregu-
lated when p19 is overexpressed (but not with the specific
p19mut overexpression), showed in this work and [7]. In-
deed, the response mechanisms described in this work
when p19, p19mut or the p21 mutant are overexpressed
correlate well with observations in H-Ras knockout (KO)
mice. These KO mice were found to be viable [28] and fi-
broblasts obtained from them had few genes that modified
their expression [20]. These findings indicate that a cellular
response mechanism is in place that overcomes the lack of
H-Ras, thereby allowing the mice to survive, and that a
strong homeostatic mechanism plays a role in controlling
p21 and p19 levels, as p21 drives cell proliferation whereas
p19 maintains a reversible cellular quiescence state [7].
The role of p19 in cancer and metastasis processes
It may be significant that H-Ras is regulated by miRNAs,
such as the let-7 miRNA family [27, 29], and that the
alternative splicing of H-Ras, which favors p19 over
p21, has consequences as regards the levels of certainmiRNAs (Fig. 1a and Additional file 1). Two of the
miRNAs upregulated by p19 (Additional file 1) have pre-
viously been reported to be of significant interest in cancer
studies: miR-342 is one of the miRNA markers for acute
promyelocytic leukemia [30, 31] and miR-206 suppresses
ERα in breast cancer cell lines and also plays a role in
muscular dystrophy [32–34]. miR-335, miR-206 and
miR-126 have been shown to significantly reduce the abil-
ity of certain cells to metastasize to the lung [23, 35]. These
latter results have driven us to further study the regulation
of miR-206 by H-Ras proteins as overexpression of p19
causes G1/S delay [7] and upregulates miR-206 (Fig. 1a).
We are aware of the limitations of those studies performed
with overexpression of a CS mutant. Having this point in
mind, we presented here experiments with KO H-Ras(−/−)
DKO H-Ras(−/−)/N-Ras(−/−) that stably express p21 or
p19. Additionally, we obtained some preliminary results
of miRNAs Taqman RT-PCR expression profile of G12S
or G12A endogenous p19 and p21 proteins in fibroblasts
cell lines established from CS tumour patients. Those re-
sults showed that miR-330, miR-335 and miR-374 are sta-
tiscaly and significally overexpressed in those CS patients
cells, and thus they are putative cadidates to be miRNAs
overexpressed in CS patients (R. García-Cruz and K.
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shown that combining p19 overexpression with a miR-206
inhibitor results in a partial decrease of the G1 phase
with a clear recovery of the G2 phase, thus indicating that
miR-206 is one of the factors contributing to the delay of
the G1/S phase. Additionally, we have shown that miR-206
is regulated by the alternative splicing of H-Ras (Fig. 3a) as
the ovexpression of p19 upregulates miR-206 more effect-
ively than p21 H-Ras when pEGPP-19 and pEGPP-21 are
stably expressed in KO H-Ras(−/−). miR-138, a miRNA that
suppresses invasion and promotes apoptosis in some car-
cinoma cells [36], was also studied. Figure 3b, c show that
miR-138 is clearly upregulated in KO H-Ras(−/−) mice that
stably express pEGPP-19, whereas it is unaffected in KO
H-Ras(−/−) mice that stably express pEGPP-21 (Fig. 3b).
This observation was corroborated by the transient expres-
sion of both proteins (Fig. 3c). Finally, we also corrob-
orated our previous studies in which we demonstrated
that p19 H-Ras does not induce growth using DKO
H-Ras/N-Ras(−/−)/(−/−) mice that stably express pEGPP-19
(see Fig. 4). As we showed here that miR-206 regulates cell
growth (being these observations in agreement with previ-
ous published results, see below) we discuss here our a
putative protein 3′-UTR target that could be having a role
on these cell growth regulation. Adams et al. have indenti-
fied ERα as a direct miR-206 target, and further demon-
strated that miR-206 inhibited the mRNA and protein
expression of ERα in human ovarian cells [32]. Addition-
ally, expression of miR-206 has been showed to inhibit
cellular proliferation and to disturb invasion in ERα–posi-
tive endometrial carcinoma cells [37].
Conclusions
H-Ras mutants have been described as a potential marker
for CS [15, 38, 39], although the mutations in IDX se-
quences and the rasISS1 splicing silencer described in [24]
have not been observed in several patients with this CS
(K. Sol-Church, personnel communication). This finding
strongly suggests that H-Ras-related mutations in CS are
likely to be found in the common amino acid sequences
and thereby affect the complementary functions of p21
and p19. We can therefore conclude that both, p21
and p19, must malfunction in order for a subject to
develop CS. Around 90 % of CS patients have the G
to A mutation that results in the G12S amino acid
change. We therefore tested how this mutation affects
a selected group of cancer-related miRNAs and found
a significant upregulation by p19 H-Ras G12S in all
cases. This allowed us to conclude that the H-Ras G12S
mutation plays an important role in miRNA expression
and therefore opens up a new line of study to under-
stand the consequences of this mutation on CS. Fur-
thermore, this finding has further consequences for
many cancers as our results indicate that oncogenesmay have a sufficiently important impact on miRNA
expression to promote their development.
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